Document is current
Any future updates will be listed below
-
Authors
Fischer, Tom T. https://orcid.org/0000-0002-2138-9102
Maaß, Kendra K. https://orcid.org/0000-0001-9357-5038
Puranachot, Pitithat https://orcid.org/0000-0002-6786-9240
Mieskolainen, Markus
Sill, Martin https://orcid.org/0000-0001-7616-7665
Schad, Paulina S.
Volz, Stefanie https://orcid.org/0009-0004-4165-8893
Rosing, Fabian https://orcid.org/0000-0003-4749-2666
Wedig, Tatjana
Schwarz, Nathalie
Finster, Agnes M. E.
Iser, Florian https://orcid.org/0009-0003-6514-817X
Meyer, Jochen https://orcid.org/0009-0000-8610-0077
Sahm, Felix https://orcid.org/0000-0001-5441-1962
Lohi, Olli https://orcid.org/0000-0001-9195-0797
Damaty, Ahmed El https://orcid.org/0000-0003-0146-8943
Brors, Benedikt https://orcid.org/0000-0001-5940-3101
Haapasalo, Hannu https://orcid.org/0000-0003-4389-7391
Pfister, Stefan M. https://orcid.org/0000-0002-5447-5322
Haapasalo, Joonas https://orcid.org/0000-0002-6468-4937
Pajtler, Kristian W. https://orcid.org/0000-0002-3562-6121
Nordfors, Kristiina https://orcid.org/0000-0002-3680-4524
-
Funding
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 13 February 2025
Accepted: 30 April 2025
First Online: 28 June 2025
Declarations
:
: The study was approved by the Finnish Committee of Ethics of Tampere University Hospital (ethics approval ID: R13050). Written, informed consent was obtained from all patients and/or their legal representatives.
: Written informed consent for the publication was obtained from all study participants, their parents, or legal guardians.
: S.M.P.: scientific advisory board at BioSkryb. M.S., S.M.P., and F.S.: co-founders and shareholders of Heidelberg Epignostix GmbH. MS has become full-time employee of Heidelberg Epignostix GmbH since July 2024.
